November 21, 2026
$RichWire Markets and money, explained simply
LIVE
Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results

Alpha Tau Medical Shares Rally After Brain Cancer Treatment Shows Complete Tumor Clearance in Trial

💳 Personal Finance 2 min read 👁 5

Alpha Tau Medical shares jumped 15.70% in premarket trading after reporting that its Alpha DaRT therapy achieved complete tumor clearance in five out of six evaluable patients with recurrent glioblastoma in an ongoing U.S. trial.

Alpha Tau Medical Shares Rally After Brain Cancer Treatment Shows Complete Tumor Clearance in Trial💳Personal Finance

Photo: Benzinga

Key points

  • Alpha Tau Medical shares rose 15.70% in premarket trading to $15.48.
  • Five out of six evaluable brain cancer patients achieved complete tumor clearance.
  • All eight trial participants remained alive with no unanticipated serious adverse events.

Alpha Tau Medical Ltd. shares climbed 15.70% to $15.48 in premarket trading on Monday following positive interim data from its U.S. clinical trial evaluating Alpha DaRT therapy for recurrent glioblastoma, a severe form of brain cancer. For everyday investors tracking medical technology equities, the sharp upward move brings the stock close to its 52-week high of $15.79.

According to trial data capturing patient outcomes through November 11, clinicians have treated eight patients, with six reaching the MRI response assessment stage. All six evaluable participants achieved an objective response under RANO criteria. Notably, five patients, representing 83.3% of the assessed group, demonstrated complete tumor clearance with no measurable disease remaining at the treated site. An additional patient experienced a partial response with a 58% tumor size reduction.

Researchers reported favorable safety outcomes alongside the tumor response rates. All eight treated patients remained alive as of the November cutoff, with a median follow-up of 6.9 months for the assessed cohort. Investigators successfully deployed the therapy in 100% of cases and noted no unanticipated serious adverse events, though one patient experienced a previously documented grade 3 seizure that resolved with treatment.

What to watch next: Enrollment in the trial continues toward a target of 20 patients, with ongoing imaging required to confirm early responses in newer participants and monitor for potential recurrence.

Source Benzinga — benzinga.com/markets/biotech/26/11/63291764/alpha-dart-therapy-show… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.